Summit Therapeutics (SMMT) Total Current Liabilities (2018 - 2026)

Summit Therapeutics (SMMT) has 9 years of Total Current Liabilities data on file, last reported at $103.6 million in Q2 2026.

• Quarterly Total Current Liabilities rose 71.68% year-over-year to $103.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $103.6 million (up 71.68% YoY) and the FY2025 annual result came in at $73.0 million, up 74.91% from the prior year.
• Total Current Liabilities grew to $103.6 million in Q2 2026, from $83.3 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $140.2 million in Q2 2024 to a low of $11.9 million in Q2 2023.
• A 5-year average of $52.3 million and a median of $40.3 million in 2022 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities sank 68.89% — and 2024, when it jumped 1074.82%.
• Tracing SMMT's Total Current Liabilities over 5 years: stood at $38.8 million in 2022, then sank by 47.39% to $20.4 million in 2023, then surged by 104.5% to $41.7 million in 2024, then soared by 74.91% to $73.0 million in 2025, then jumped by 41.89% to $103.6 million in 2026.
• The last three Total Current Liabilities figures came in at $103.6 million (Q2 2026), $83.3 million (Q1 2026), and $73.0 million (Q4 2025), per Business Quant data.